8-K - Armata Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Armata Pharmaceuticals, Inc. announced a delay in its fourth quarter and full-year 2025 financial results announcement, anticipating filing its Form 10-K on or before March 31, 2026, and provided a corporate update including FDA QIDP designation for AP-SA02, Phase 3 trial plans, cGMP facility commissioning, and positive Phase 2a study results.

Key Takeaways

1Delayed Q4 and FY 2025 financial results announcement; 10-K filing by 2026-03-31.

2FDA granted QIDP designation to AP-SA02 for adjunct treatment of complicated S. aureus bacteremia caused by MSSA or MRSA.

3End-of-Phase 2 FDA response confirms advancement of AP-SA02 to Phase 3 study in complicated SAB, initiation anticipated in H2 2026.

4cGMP manufacturing facility in Los Angeles, California (56,000 sq ft) formally commissioned with full production runs completed.

5Phase 2a diSArm study of AP-SA02 showed higher cure rate at day 12, 100% response without relapse, and trends toward rapid normalization of mortality predictors.

6Submitted FDA request for Fast Track Designation for AP-SA02.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, a

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 19, 2026. 104 Cover Page Interactive Data File (embedde

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1